DR-30207

N/A

Report date: 2024/11/15 19:12:05

Base Information

Drug NameDR-30207

Drug Alias NameDR-30207

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody

Mechanisms of ActionProgrammed death-ligand 1 blockersTransforming growth factor beta inhibitorsVascular endothelial growth factor inhibitors

TargetsTransforming growth factor betaProgrammed death-ligand 1Vascular endothelial growth factor

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesZhejiang Doer Biologics Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesZhejiang Doer Biologics Corp

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A